JP2021521248A5 - - Google Patents

Info

Publication number
JP2021521248A5
JP2021521248A5 JP2020558506A JP2020558506A JP2021521248A5 JP 2021521248 A5 JP2021521248 A5 JP 2021521248A5 JP 2020558506 A JP2020558506 A JP 2020558506A JP 2020558506 A JP2020558506 A JP 2020558506A JP 2021521248 A5 JP2021521248 A5 JP 2021521248A5
Authority
JP
Japan
Prior art keywords
olfr
olfrs
expression
use according
olfactory receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020558506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521248A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/027558 external-priority patent/WO2019204233A1/en
Publication of JP2021521248A publication Critical patent/JP2021521248A/ja
Publication of JP2021521248A5 publication Critical patent/JP2021521248A5/ja
Pending legal-status Critical Current

Links

JP2020558506A 2018-04-16 2019-04-15 嗅覚受容体活性を標的とすることによる免疫応答のモジュレート Pending JP2021521248A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862658581P 2018-04-16 2018-04-16
US62/658,581 2018-04-16
PCT/US2019/027558 WO2019204233A1 (en) 2018-04-16 2019-04-15 Modulating immune response via targeting of olfactory receptor activity

Publications (2)

Publication Number Publication Date
JP2021521248A JP2021521248A (ja) 2021-08-26
JP2021521248A5 true JP2021521248A5 (enExample) 2022-04-25

Family

ID=68240310

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020558506A Pending JP2021521248A (ja) 2018-04-16 2019-04-15 嗅覚受容体活性を標的とすることによる免疫応答のモジュレート

Country Status (4)

Country Link
US (1) US20210145768A1 (enExample)
EP (1) EP3781173A4 (enExample)
JP (1) JP2021521248A (enExample)
WO (1) WO2019204233A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3827816A1 (en) * 2019-11-28 2021-06-02 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Prooxidative chain-transfer agents for use in the treatment of malignant tumour or infectious diseases
WO2021257905A2 (en) * 2020-06-17 2021-12-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Olfactory receptors for use as targets for antigen binding molecules to detect and treat cancer
WO2022128050A1 (en) * 2020-12-14 2022-06-23 Symrise Ag Medicament for fighting inflammation and pain
JP2022187352A (ja) * 2021-06-07 2022-12-19 エステー株式会社 嗅覚受容体の阻害剤、消臭剤、消臭方法
JP2023084473A (ja) * 2021-12-07 2023-06-19 花王株式会社 フェノール化合物を原因とするにおいの抑制剤の評価及び／又は選択方法
EP4241766A1 (en) * 2022-03-07 2023-09-13 Fondazione Per L'Istituto Oncologico Di Ricerca (IOR) Use of olfactory receptor or13a1 ligands in the treatment of lymphomas
IT202200010358A1 (it) * 2022-05-18 2023-11-18 Giuliani Spa Agonista del recettore olfattivo 2a4/7 per promuovere la crescita di capelli e migliorare l’aspetto estetico / olfactory receptor 2a4/7 agonist for promoting hair growth and improving aesthetic aspect
CN115840026B (zh) * 2023-02-13 2023-05-23 汉王科技股份有限公司 嗅觉受体在识别4-甲氧基苯甲醛中的用途和检测4-甲氧基苯甲醛的方法
KR20250044488A (ko) * 2023-09-21 2025-04-01 성균관대학교산학협력단 후각수용체 Olfr164를 제어하는 패혈증 치료용 조성물
CN118178367B (zh) * 2023-12-11 2024-09-13 南方医科大学 一种治疗胶质母细胞瘤的药物及其应用
US12290550B1 (en) 2023-12-27 2025-05-06 Olfactive Ai, Inc. Compositions and methods for treating endocrine diseases and disorders
US12102611B2 (en) * 2024-03-25 2024-10-01 Olfactive Biosolutions, LLC Compositions and methods for treating hypertension by modulating endocrine activity
WO2025187455A1 (ja) * 2024-03-08 2025-09-12 株式会社 資生堂 メラノサイトに対する紫外線の影響の抑制剤
CN120960185A (zh) * 2025-09-03 2025-11-18 江西农业大学 麝香酮在制备病毒抑制剂中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006008074B4 (de) * 2006-02-22 2013-08-14 RUHR-UNIVERSITäT BOCHUM Behandlung von Krebs mit Geruchsrezeptor-Liganden
US20110196383A1 (en) * 2009-05-05 2011-08-11 Atherolysis Medical, Inc Atherosclerotic Plaque Dissolution Composition
AU2011281062B2 (en) 2010-07-21 2015-01-22 Board Of Regents, The University Of Texas System Methods and compositions for modification of a HLA locus
KR101050436B1 (ko) * 2010-12-09 2011-07-19 연세대학교 산학협력단 대사질환과 연관된 후각수용체 유전자 및 그의 용도
WO2013061487A1 (ja) * 2011-10-26 2013-05-02 パナソニック株式会社 マウス嗅覚受容体Ｏｌｆｒ１５を細胞膜に発現する方法
JP2016535060A (ja) * 2013-08-27 2016-11-10 ドイチェス クレブスフォルシュングスツェントルムＤｅｕｔｓｃｈｅｓ Ｋｒｅｂｓｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ 細胞傷害性ｔ細胞応答の修飾物質
US11123292B2 (en) * 2014-01-29 2021-09-21 Catherine S. Beaudin Use of biocompatible microdroplets for the treatment of atherosclerosis, heart disease and stroke
CN103976987A (zh) * 2014-06-04 2014-08-13 古天津 一种用于治疗动脉粥状硬化的组合物
CN106668050A (zh) * 2017-01-22 2017-05-17 新乡医学院 治疗动脉粥样硬化的药物组合物及应用

Similar Documents

Publication Publication Date Title
JP2021521248A5 (enExample)
Brodeur Spontaneous regression of neuroblastoma
Liepelt et al. Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases
Wang et al. Targeting IL-10 family cytokines for the treatment of human diseases
Diorio et al. Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
Zhang et al. Neutrophils in cancer development and progression: roles, mechanisms, and implications
Germano et al. Cytokines as a key component of cancer-related inflammation
Yamanishi et al. Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis
Yasmin et al. Epigenetic regulation of inflammatory cytokines and associated genes in human malignancies
JP2548525B2 (ja) 腫瘍壊死因子をコードする組換ｄｎａ分子
JP2022036182A (ja) Ｂ型肝炎感染症治療用のＰＡＰＤ５又はＰＡＰＤ７のｍＲＮＡ減少用核酸分子
Cao et al. Targeting inflammation with chimeric antigen receptor macrophages using a signal switch
Deng et al. Understanding the complexity of the tumor microenvironment in K-ras mutant lung cancer: finding an alternative path to prevention and treatment
JP2020503010A5 (enExample)
JP2020537501A5 (enExample)
Zitzmann et al. SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells
Mukherjee et al. TAM receptor tyrosine kinase function and the immunopathology of liver disease
JP2021512056A (ja) 細胞活性状態を調節することにより免疫細胞の炎症状態をインビボで変更すること
RU2021130306A (ru) Композиции il-12, нацеленные на edb
BR122020018622A2 (pt) Molécula de ácido nucleico para redução de papd5 e papd7 de mrna para o tratamento de infecção hepatite b
Weidenbusch et al. Interleukin-22 in kidney injury and regeneration
US20210292327A1 (en) Deuterated toll-like receptor modulators
JP2020033363A (ja) 二重誘導体化キトサンナノ粒子、並びに生体内での遺伝子導入のためのその製造、及び使用方法
TW201010698A (en) Treatment or prevention of hepatitis C with immunomodulator compounds
JP2020529418A (ja) Ｔ細胞急性リンパ芽球性白血病を治療するための化合物、組成及び方法